As a pharmacologic control, the cells are treated with increasing doses of TRC-766, which is structurally similar to PP2A (SMAP) but biologically inactive. TRC-766 lacks a key N-H sulfonamide hydrogen bond donor. While TRC-766 still binds PP2A, it does not activate the phosphatase and therefore it was postulated to not affect cell viability[1].